Scribe Therapeutics, Inc. (SCTX) insider trading.
In Q3 2026, insiders at Scribe Therapeutics, Inc. reported 14 non-derivative transactions on 25 Forms 3, 4 and 5: 9 open-market purchases worth $71.3M and 0 sales.
- Transactions
- 14
- Purchases (P)
- 9
- Sales (S)
- 0
- Net shares, P minus S
- 4,730,237
- Insiders
- 7
- Last filed
- 2026-07-29
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Avoro Ventures LLC / Avoro Capital Advisors LLC / Aghazadeh Behzad | Director, Other, TenPercentOwner | 3 | 3 | 0 |
| AH Equity Partners Bio II, L.L.C. / AH Bio Fund II, L.P. / Andreessen Marc L / AH Equity Partners Bio III, L.L.C. / HOROWITZ BENJAMIN A / AH Bio Fund III, L.P. | TenPercentOwner | 3 | 1 | 0 |
| ORBIMED ADVISORS LLC / OrbiMed Capital GP VIII LLC | Director | 2 | 1 | 0 |
| Gordon Carl L | Director | 2 | 1 | 0 |
| Parrot David | Officer · Chief Financial Officer | 2 | 2 | 0 |
| Doudna Jennifer A | TenPercentOwner | 1 | 0 | 0 |
| Lucas Svetlana | Officer · Chief Business Officer | 1 | 1 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-28 | Avoro Ventures LLC / Avoro Capital Advisors LLC / Aghazadeh Behzad | P (A) | 7,905 | $18.25 | 3,088,888 | Form 4 |
| 2026-07-27 | ORBIMED ADVISORS LLC / OrbiMed Capital GP VIII LLC | P (A) | 1,000,000 | $15 | 1,348,825 | Form 4 |
| 2026-07-27 | ORBIMED ADVISORS LLC / OrbiMed Capital GP VIII LLC | C (A) | 348,825 | — | 348,825 | Form 4 |
| 2026-07-27 | Gordon Carl L | P (A) | 1,000,000 | $15 | 1,348,825 | Form 4 |
| 2026-07-27 | Gordon Carl L | C (A) | 348,825 | — | 348,825 | Form 4 |
| 2026-07-27 | AH Equity Partners Bio II, L.L.C. / AH Bio Fund II, L.P. / Andreessen Marc L / AH Equity Partners Bio III, L.L.C. / HOROWITZ BENJAMIN A / AH Bio Fund III, L.P. | P (A) | 333,333 | $15 | 2,385,075 | Form 4 |
| 2026-07-27 | AH Equity Partners Bio II, L.L.C. / AH Bio Fund II, L.P. / Andreessen Marc L / AH Equity Partners Bio III, L.L.C. / HOROWITZ BENJAMIN A / AH Bio Fund III, L.P. | C (A) | 697,650 | — | 697,650 | Form 4 |
| 2026-07-27 | AH Equity Partners Bio II, L.L.C. / AH Bio Fund II, L.P. / Andreessen Marc L / AH Equity Partners Bio III, L.L.C. / HOROWITZ BENJAMIN A / AH Bio Fund III, L.P. | C (A) | 2,051,742 | — | 2,051,742 | Form 4 |
| 2026-07-27 | Doudna Jennifer A | C (A) | 12,511 | — | 603,547 | Form 4 |
| 2026-07-24 | Avoro Ventures LLC / Avoro Capital Advisors LLC / Aghazadeh Behzad | P (A) | 50,000 | $22.31 | 3,080,983 | Form 4 |
| 2026-07-24 | Avoro Ventures LLC / Avoro Capital Advisors LLC / Aghazadeh Behzad | P (A) | 2,333,333 | $15 | 3,030,983 | Form 4 |
| 2026-07-23 | Lucas Svetlana | P (A) | 3,000 | $15 | 3,000 | Form 4 |
| 2026-07-23 | Parrot David | P (A) | 1,333 | $15 | 1,333 | Form 4 |
| 2026-07-23 | Parrot David | P (A) | 1,333 | $15 | 1,333 | Form 4 |
Transaction codes in this quarter
Get SCTX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1853921&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · SCTX company page · Scribe Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Scribe Therapeutics, Inc. (SCTX)?
In Q3 2026, insiders at Scribe Therapeutics, Inc. reported 14 non-derivative transactions on 25 Forms 3, 4 and 5: 9 open-market purchases worth $71.3M and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Scribe Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/sctx.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.